SEC Form 10-K Summary
Registrant: Rodgers Silicon Valley Acquisition Corp. (RSVA), a blank-check company that subsequently agreed to merge with Enovix Corporation. Reporting period: September 23, 2020 inception through December 31, 2020. The filing was signed March 8, 2021.
Business Context and Reporting Period
RSVA was formed to complete a merger, share exchange, asset acquisition, stock purchase, recapitalization or similar business combination. It had no operating business or operating revenue during the reporting period and conducted only formation, IPO, target-identification and related activities.
On February 22, 2021, after year-end, RSVA entered into a merger agreement with Enovix Corporation. The proposed transaction would make Enovix a wholly owned subsidiary and rename the combined company Enovix Corporation. The agreement contemplated approximately $1.05 billion of stock consideration, represented by 105 million RSVA shares valued at $10 per share, subject to the agreement’s conditions and adjustments.
Key Financial Metrics
| Metric | Period-end or period amount |
|---|---|
| Operating revenue | $0; the company did not expect operating revenue before a business combination |
| Operating and formation costs | $169,324 |
| Net loss | $202,287 |
| Net loss per non-redeemable common share | $0.03 basic and diluted loss |
| Cash used in operating activities | $250,640 |
| Cash | $773,086 |
| Marketable securities in trust account | $229,967,028 |
| Total assets | $230,906,193 |
| Total liabilities | $8,134,754 |
| Common stock subject to possible redemption | $217,771,437 for 21,780,266 shares |
| Stockholders’ equity | $5,000,002 |
| Debt | No long-term debt; a $50,000 related-party promissory note was repaid on December 8, 2020 |
RSVA completed its IPO on December 4, 2020, selling 23 million units at $10 per unit for gross proceeds of $230 million. It also sold 6 million private placement warrants for $6 million. Transaction costs totaled $13,051,274, including $8,050,000 of deferred underwriting fees payable only if a business combination is completed.
The trust account was funded with $230 million and invested primarily in U.S. Treasury securities and money market investments. Interest income was $5,877, offset by a $38,849 unrealized loss on trust-account securities. The filing does not provide meaningful operating margins because the company had no operating revenue.
Material Changes and Subsequent Events
- The company transitioned from formation to a publicly traded SPAC following the December 4, 2020 IPO.
- Units began trading on Nasdaq under RSVAU on December 4, 2020; the common stock and warrants began separate trading on January 4, 2021 under RSVA and RSVAW.
- On February 22, 2021, RSVA announced the proposed Enovix business combination.
- RSVA also entered into PIPE subscription agreements for 12.5 million shares at $14 per share, expected to generate $175 million immediately before or at the business-combination closing.
- There is no prior comparable operating period because RSVA was incorporated on September 23, 2020 and had no operating business.
Guidance, Outlook, Risks and Unusual Items
- RSVA had until December 4, 2022 to complete a business combination or liquidate, absent an approved extension. If liquidation occurred, public shares generally would be redeemed from the trust account, while warrants could expire worthless.
- Public stockholders were entitled to redeem shares in connection with a business combination, creating potential funding and dilution uncertainty.
- The proposed Enovix transaction remained subject to closing conditions, stockholder approval or applicable tender-offer procedures, potential redemptions and other transaction requirements.
- The company’s principal risks included failure to complete a business combination, insufficient funds to complete a transaction, competition from other SPACs and acquisition sources, sponsor and management conflicts of interest, dilution from founder shares, warrants and PIPE shares, and dependence on the trust account.
- COVID-19 could delay target discussions, due diligence, travel, negotiations and transaction closing. The specific financial impact was not determinable at year-end.
- The sponsor received 5.75 million founder shares for $25,000 and purchased 6 million private warrants for $6 million. Management and directors had other business affiliations, including affiliations with Enovix, creating potential conflicts that investors should evaluate.
- Management stated that post-IPO funds outside the trust account were sufficient to sustain operations through March 8, 2022, alleviating substantial doubt about going concern at the financial-statement issuance date.
- Disclosure controls were assessed as effective as of December 31, 2020. No management assessment or auditor attestation of internal control over financial reporting was required for this newly public emerging growth company.
Most Important Facts for Investors to Verify
- Verify the final status, terms, valuation, closing conditions and post-closing capitalization of the RSVA-Enovix merger.
- Verify actual public-share redemptions and the amount of trust-account cash available at closing.
- Review the Enovix operating results, cash burn, manufacturing plans, customer commitments and financing needs, which are not provided in this SPAC’s 2020 financial statements.
- Quantify dilution from the 105 million merger shares, 12.5 million PIPE shares, 17.5 million public and private warrants, founder shares and any converted working-capital loans.
- Confirm payment or waiver of the $8.05 million deferred underwriting fee and any additional transaction expenses.
- Assess sponsor, director and officer conflicts, particularly the overlap between RSVA leadership and Enovix or other portfolio companies.
- Review the definitive proxy statement, merger agreement, PIPE agreements and subsequent SEC filings for amended terms, risk factors and financial projections.